Alcodez ic

Alcodez ic has detoxifying, anti-alcohol and hepatoprotective activity. It activates the activity of intrahepatic enzymes that are participants in the metabolic processes of ethanol (ADH with ALDH), which allows increasing the rate of excretion of acetaldehyde with ethanol from the body by weakening their toxic properties.

The drug increases the resistance of hepatocytes to the products of lipid peroxidation, which develops under the influence of various toxic elements, including ethanol. It prevents the accumulation of fats inside hepatocytes, due to which fatty intrahepatic infiltration does not occur. At the same time, the drug prevents the formation of collagen with fibronectin and slows the development of liver cirrhosis. [ 1 ]

Indications Alcodez ic

It is used for the following disorders:

• reducing the toxic effects of alcohol;
• active phase of alcohol poisoning (moderate or mild);
• alcohol withdrawal;
• chronic alcoholism;
• combined treatment of liver pathologies (especially those of alcoholic origin).

Release form

The medicinal element is released in tablets - 4 pieces inside a cell pack (1 pack inside a box) or 10 pieces inside a blister pack (2 packs inside a pack).

Pharmacodynamics

The medicine activates the activity of GABA and cholinergic neurotransmitter structures, which improves mental work and the functioning of short-term memory. Prevents the development of motor excitation associated with ethyl alcohol.

Alcodez ic has a non-specific anxiolytic and antidepressant effect, and also reduces the craving for alcohol. Reduces the period of withdrawal, and at the same time reduces the somatic and mental symptoms associated with a hangover.

Pharmacokinetics

Metadoxine is absorbed at high speed, entering the gastrointestinal tract, having high bioavailability values (60-80%). Protein synthesis rates are 50%.

Metabolic processes are carried out inside the liver; in this process, metabolic elements with medicinal activity are formed – pyridoxine with pyrrolidone carboxylate.

The half-life of metadoxine after oral or parenteral administration is 40-60 minutes. Metadoxine excretion with urine is 45-50% and occurs within 24 hours. With feces, 35-50% of the drug is excreted within 96 hours.

Dosing and administration

The medication is taken orally.

To reduce the toxic effects of alcoholic beverages: take 2 tablets 0.5-1 hour before drinking alcohol, or 1 tablet 0.5-1 hour before and another 1 tablet within half an hour after drinking alcohol.

In case of active phase of alcohol poisoning (moderate or mild intensity) or alcohol withdrawal: 1 tablet 2 times a day 15-30 minutes before meals. The daily dosage can also be increased to 3 tablets. The therapeutic cycle lasts 3-7 days (depending on the patient's condition).

During combined treatment of liver pathologies or chronic stage of alcoholism: 1 tablet 2 times a day, 15-30 minutes before eating. A maximum of 3 tablets of the drug are allowed per day. Such treatment should last at least 1.5 months.

• Application for children

It is prohibited to use the medication in pediatrics, because there is no experience with the use of the drug for this age group.

Use Alcodez ic during pregnancy

Alcodez ic should not be prescribed to pregnant or breastfeeding women.

Contraindications

Contraindicated for use in people with severe intolerance to elements of the drug.

Side effects Alcodez ic

Side effects when taking the medicine may include allergy symptoms.

Interactions with other drugs

The combination of metadoxine with levodopa leads to a weakening of its medicinal effect (due to the potentiation of decarboxylation).

Storage conditions

Alcodez ic must be stored in a place that is closed to small children. The temperature level is no more than 25°C.

Shelf life

Alcodez ic can be used within a 3-year period from the date of sale of the therapeutic substance.

Analogues

Analogues of the drug are Medichronal, Proproten with Liveria ic, and also Kolme.